Stately Bio: $12 Million Closed For Developing Regenerative Medicines With Cellular Imaging Platform
Stately Bio, a company developing cell therapies using an ML-based live-cell imaging platform, announced $12 million in seed funding led by AIX Ventures, with participation from Dimension Capital, ...
With the FDA approval for Tregzi, Orca Bio has become one of the very few U.S.-based commercial drugmaker that remains privately held. (Getty Images) Orca Bio has jumped into the commercial market ...
Preliminary nine-month follow-up shows more than twice the CAR-T persistence observed in a dose-matched prior cohort using conventional bead activation Synecta™ T1 Enhanced now available to support ...
TranscriptFormer maps gene-expression profiles from 112 million cells across 12 species, enabling cross-species comparisons, cell-type identification in an unseen species and separation of healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results